- 全部删除
- 您的购物车当前为空
Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent CXCR4 antagonist and an anti-angiogenic drug that is of potential value in treating choroid neovascularization.
为众多的药物研发团队赋能,
让新药发现更简单!
Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent CXCR4 antagonist and an anti-angiogenic drug that is of potential value in treating choroid neovascularization.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | ¥ 990 | 6-8周 | |
10 mg | ¥ 1,580 | 6-8周 | |
25 mg | ¥ 2,850 | 6-8周 | |
50 mg | ¥ 4,640 | 6-8周 | |
100 mg | ¥ 7,170 | 6-8周 | |
200 mg | ¥ 11,800 | 6-8周 | |
500 mg | ¥ 23,800 | 6-8周 |
Burixafor hydrobromide 相关产品
产品描述 | Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent CXCR4 antagonist and an anti-angiogenic drug that is of potential value in treating choroid neovascularization. |
体外活性 | Burixafor hydrobromide mobilizes mesenchymal stem cells, attenuates inflammation, and preserves cardiac systolic function in a porcine model of myocardial infarction [2]. |
别名 | TG-0054 hydrobromide |
分子量 | 647.644 |
分子式 | C27H52BrN8O3P |
CAS No. | 1191450-19-7 |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
溶解度信息 | H2O: 50 mg/mL (65.02 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
H2O
|
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
评论内容